{"id":"W3005184972","doi":"10.1016/j.jaad.2020.01.072","title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":70,"is_retracted":false,"has_abstract":false,"ca_institutions":"Lynde Centre for Dermatology","funders":"Janssen Biotech; Ortho Dermatologics; LEO Pharma; Sanofi Genzyme; GlaxoSmithKline; Australian Renewable Energy Agency; MedImmune; Kyowa Hakko Kirin; Sun Pharma; Dermira; UCB Pharma; Valeant Pharmaceuticals International; Medac; AbbVie; Novartis; Celgene; Regeneron Pharmaceuticals; University of Connecticut; Amgen; Meiji Seika Pharma; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Almirall","keywords":"Medicine; Apremilast; Scalp; Placebo; Dermatology; Multicenter study; Double blind; Psoriasis; Randomized controlled trial; Adverse effect; Multicenter trial; Surgery; Internal medicine; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002146992,0.001389201,0.003233305,0.0004082472,0.0004739831,0.0008043852,0.0007233294,0.00171596,0.003200137],"category_scores_gemma":[0.001743052,0.0006678416,0.001479637,0.0003956979,0.001100822,0.001100924,0.0002415235,0.002256923,0.0005892925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003182828,"about_ca_system_score_gemma":0.0007031323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004022507,"about_ca_topic_score_gemma":0.000628317,"domain_scores_codex":[0.9992901,0.0004168205,0.00005285832,0.00008937217,0.00007184393,0.00007893478],"domain_scores_gemma":[0.9988594,0.0004187236,0.0002404306,0.00008637879,0.00007535687,0.0003196813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9574885,0.009677477,0.001100355,0.0007304567,0.0007542809,0.00007972087,0.00006737967,0.000275044,0.008341014,0.00006332523,0.0005527402,0.02086966],"study_design_scores_gemma":[0.8774296,0.1153715,0.005162093,0.000023221,0.0003632465,0.00008758368,0.00002549321,0.0003065773,0.0007065893,0.00008707772,0.0004169061,0.00002010678],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889024,0.006635859,0.0006301579,0.000382073,0.000227715,0.001336807,0.0005532714,0.000113568,0.001218093],"genre_scores_gemma":[0.9918759,0.002888679,0.001109392,0.0008011298,0.0004315227,0.001007201,0.0006140917,0.0000276846,0.001244408],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003233305,"threshold_uncertainty_score":0.01135451,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01734425170394657,"score_gpt":0.2760336491930642,"score_spread":0.2586893974891176,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}